利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

85 条记录 (耗时 0.021 秒)

    Chemoablation of tissue using biodegradable, solid salt dosage forms
    1.
    发明授权
    Chemoablation of tissue using biodegradable, solid salt dosage forms 有权
    使用可生物降解的固体盐剂型对组织进行化学消融

    公开(公告)号：US08389023B2

    公开(公告)日：2013-03-05

    申请号：US13241952

    申请日：2011-09-23

    申请人： Joseph V. DiTrolio

    发明人： Joseph V. DiTrolio

    IPC分类号： A61K33/14 ,  A61B17/42 ,  A61M5/178 ,  A61M31/00 ,  A61M25/06 ,  A61M5/315

    CPC分类号： A61K9/0024 ,  A61K33/14 ,  A61M37/0069 ,  Y10S514/951 ,  Y10S514/955 ,  Y10S514/966 ,  Y10S514/968

    摘要： Novel methods for the chemical ablation of tissue (e.g. prostatic tissue) are described. These methods include the steps of: (a) providing one or more solid salt dosage form comprising 50-100% w/w salt; and (b) inserting one or more of such solid salt dosage forms into the tissue. The solid salt dosage form is optionally inserted into the tissue under real-time ultrasonic observation. An advantage of the present invention is its ability to eliminate toxic byproducts. For example, where NaCl-based solid salt dosage forms are used to effect localized chemical ablation, the concentration is ultimately reduced to the level of normal saline (i.e., about 0.9%) upon absorption by the body of the subject being treated.

    摘要翻译： 描述了用于组织（例如前列腺组织）的化学消融的新方法。 这些方法包括以下步骤：（a）提供一种或多种包含50-100％w / w盐的固体盐剂型; 和（b）将一种或多种这样的固体盐剂型插入组织中。 在实时超声波观察下，将固体盐剂型任选地插入组织。 本发明的优点是其消除有毒副产物的能力。 例如，当使用基于NaCl的固体盐剂型来实现局部化学消融时，在被被治疗的受试者的身体吸收时，浓度最终降低到生理盐水的水平（即约0.9％）。

    Composition for treating abnormal conditions of the epithelium of bodily orifices
    7.
    发明授权
    Composition for treating abnormal conditions of the epithelium of bodily orifices 有权
    用于治疗身体上皮的异常状况的组合物

    公开(公告)号：US6017554A

    公开(公告)日：2000-01-25

    申请号：US189782

    申请日：1998-09-21

    申请人： Perry A. Ratcliff

    发明人： Perry A. Ratcliff

    IPC分类号： A61K8/20 ,  A61K8/22 ,  A61K8/24 ,  A61K9/00 ,  A61K33/40 ,  A61K33/42 ,  A61K47/02 ,  A61Q11/00 ,  A61Q15/00 ,  A61Q19/00 ,  A61K33/00

    CPC分类号： A61K47/02 ,  A61K33/40 ,  A61K33/42 ,  A61K8/20 ,  A61K8/22 ,  A61K8/24 ,  A61K9/0014 ,  A61Q11/00 ,  A61Q15/00 ,  Y10S424/15 ,  Y10S514/944 ,  Y10S514/945 ,  Y10S514/966 ,  Y10S514/967 ,  Y10S514/968

    摘要： A stable solution cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonoas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH stabilized chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

    摘要翻译： 公开了用于预防和治疗身体上皮的异常状况的稳定的溶液霜剂，药膏或喷雾组合物，其包含活化的稳定的二氧化氯和磷酸盐，例如磷酸氢二钠，磷酸二氢钠，磷酸三钠和单氟磷酸钠 孔。 直肠，阴道，尿道，口腔，鼻，眼和耳道孔的上皮的这种异常状况的实例包括细菌感染，例如放线杆菌放线杆菌和牙龈卟啉单胞菌，以及真菌感染如假丝酵母和白斑。 优选的浓度范围为约0.005％-2.0％二氧化氯和约0.02％-3.0％磷酸盐。 磷酸盐化合物在6.0至7.4的pH范围内阻止二氧化氯的逸出，在此pH值稳定的二氧化氯被激活并释放足够的二氧化氯以降低运动性并对所涉及的微生物致死。

    Method for treating the epithelium of bodily orifices with chlorine dioxide and a phosphate compound
    10.
    发明授权
    Method for treating the epithelium of bodily orifices with chlorine dioxide and a phosphate compound 失效
    用二氧化氯和磷酸盐化合物处理身体孔的上皮的方法

    公开(公告)号：US5902575A

    公开(公告)日：1999-05-11

    申请号：US66705

    申请日：1998-04-27

    申请人： Perry A. Ratcliff

    发明人： Perry A. Ratcliff

    IPC分类号： A61K8/20 ,  A61K8/22 ,  A61K8/24 ,  A61K9/00 ,  A61K33/40 ,  A61K33/42 ,  A61K47/02 ,  A61Q11/00 ,  A61Q15/00 ,  A61Q19/00 ,  A61K9/10

    CPC分类号： A61K47/02 ,  A61K33/40 ,  A61K33/42 ,  A61K8/20 ,  A61K8/22 ,  A61K8/24 ,  A61K9/0014 ,  A61Q11/00 ,  A61Q15/00 ,  Y10S424/15 ,  Y10S514/944 ,  Y10S514/945 ,  Y10S514/966 ,  Y10S514/967 ,  Y10S514/968

    摘要： A stable solution, cream, salve, or spray composition containing chlorine dioxide and a phosphate, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices brought about by any of leukoplakia, hairy leukoplakia, vaginitis, endometriosis, Candida Albicans, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Pseudomonades, Candida species, and leukoplakia vulvae. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

    摘要翻译： 公开了含有二氧化氯和磷酸盐如磷酸氢二钠，磷酸二氢钠，磷酸三钠和单氟磷酸钠的稳定溶液，霜剂，药膏或喷雾剂，用于预防和治疗身体上皮的异常状况 孔。 由白斑，毛状白斑，阴道炎，子宫内膜异位症，白色念珠菌，放线杆菌放线菌，牙龈卟啉单胞菌，假单胞菌中的任何一种引起的直肠，阴道，尿道，口腔，鼻，眼和耳道孔的上皮的这种异常状况的例子 ，念珠菌属和外阴白斑。 优选的浓度范围为约0.005％-2.0％二氧化氯和约0.02％-3.0％磷酸盐。 磷酸盐化合物在6.0至7.4的pH范围内阻止二氧化氯的逸出，pH值二氧化氯活化并释放足够的二氧化氯以降低活性并对所涉及的微生物致死。